In the original article, author Mintu Pal was mistakenly affiliated with - “Biotechnology Division, North East Institute of Science and Technology, Jorhat, India” as published. The correct affiliation should be – “Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Bathinda, Punjab, India” as above.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
lung adenocarcinoma, inflammatory response-related gene, DNA methylation, ceRNA, immune cell infiltration, drug sensitivity
Citation
Li X, Yuan Y, Pal M and Jiang X (2022) Corrigendum: identification and validation of lncRNA-SNHG17 in lung adenocarcinoma: a novel prognostic and diagnostic indicator. Front. Oncol. 12:972329. doi: 10.3389/fonc.2022.972329
Received
18 June 2022
Accepted
01 July 2022
Published
26 July 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2022
Updates
Copyright
© 2022 Li, Yuan, Pal and Jiang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiulin Jiang, jiangxiulin@mail.kiz.ac.cn; Mintu Pal, mpal24@yahoo.com
†These authors have contributed equally to this work
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.